Familial-genetic dilated cardiomyopathy
Methodology & AI Transparency ⓘ
Familial-genetic dilated cardiomyopathy Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: For patients presenting with Familial-genetic dilated cardiomyopathy (ICD-10-CM I42.01), Heart & Cardiovascular Disease protocols prioritize ambulatory rhythm monitoring [Familial-genetic dilated cardiomyopathy I42.01] paired with baseline and interval NT-proBNP [Familial-genetic dilated cardiomyopathy I42.01] assessment.
- 2 Real-world patient consensus: Federal ICD-10-CM code I42.01 categorizes Familial-genetic dilated cardiomyopathy under Heart & Cardiovascular Disease.
- 3 Typical cash cost range: Differential triage of Familial-genetic dilated cardiomyopathy (I42.01) utilizes ambulatory rhythm monitoring [Familial-genetic dilated cardiomyopathy I42.01].
- 4 Top reported side effects / signs: Longitudinal Familial-genetic dilated cardiomyopathy monitoring tracks NT-proBNP [Familial-genetic dilated cardiomyopathy I42.01] toward < 100 pg/mL (I42.01).
Ask our AI Specialists anything about Familial-genetic dilated cardiomyopathy
What Is Familial-genetic dilated cardiomyopathy?
For patients presenting with Familial-genetic dilated cardiomyopathy (ICD-10-CM I42.01), Heart & Cardiovascular Disease protocols prioritize ambulatory rhythm monitoring [Familial-genetic dilated cardiomyopathy I42.01] paired with baseline and interval NT-proBNP [Familial-genetic dilated cardiomyopathy I42.01] assessment.
Pathophysiology, Underlying Causes & Clinical Presentation
In Familial-genetic dilated cardiomyopathy (I42.01), physiological disruption stems from myocardial oxygen supply-demand in Familial-genetic dilated cardiomyopathy (I42.01: mismatch), informing Heart & Cardiovascular Disease protocols that track High-Sensitivity Troponin I [Familial-genetic dilated cardiomyopathy I42.01] (< 14 ng/L (I42.01)).
Common Symptoms & Clinical Signs
- • Presentation of Familial-genetic dilated cardiomyopathy (I42.01): unexplained lower-extremity ankle in Familial-genetic dilated cardiomyopathy (I42.01: edema or rapid)
- • Secondary Familial-genetic dilated cardiomyopathy clinical sign: reduced exercise tolerance in Familial-genetic dilated cardiomyopathy (I42.01: and premature cardiovascular)
- • Symptom flares in Familial-genetic dilated cardiomyopathy correlating with NT-proBNP [Familial-genetic dilated cardiomyopathy I42.01] deviation outside < 100 pg/mL (I42.01)
- • Functional heart & vascular impact requiring ambulatory rhythm monitoring [Familial-genetic dilated cardiomyopathy I42.01] evaluation (I42.01)
Familial-genetic dilated cardiomyopathy Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | I42.01 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Heart & Cardiovascular Disease | NLM Clinical Tables |
| Diagnostic / Lab Marker: NT-proBNP [Familial-genetic dilated cardiomyopathy I42.01] | < 100 pg/mL (I42.01) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: High-Sensitivity Troponin I [Familial-genetic dilated cardiomyopathy I42.01] | < 14 ng/L (I42.01) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Apolipoprotein B (ApoB) [Familial-genetic dilated cardiomyopathy I42.01] | < 70 mg/dL (I42.01) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Familial-genetic dilated cardiomyopathy
Treatment selection for Familial-genetic dilated cardiomyopathy depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Familial-genetic dilated cardiomyopathy)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Long-Term safety and real-world benefits of Bempedoic Acid in Patients With: What a 1,462-Participant Study Found Bempedoic acid was generally well tolerated and demonstrated sustained efficacy with up to 2.5 years of continuous treatment. The American journal of cardiology • 2022-07-01 • Phase III Randomized Trial | N = 1,462 | 96/100 | PMID 35483979 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of ezetimibe coadministered with atorvastatin or simvastatin Ezetimibe coadministered with atorvastatin or simvastatin in patients with HoFH produced clinically important LDL-C reductions compared with best current therapy. Circulation • 2002-05-28 • Randomized Controlled Trial | N = 25 | 88/100 | PMID 12034651 ↗ |
| Rosuvastatin vs. Atorvastatin: Which Works Better for Heterozygous familial high cholesterol? Both treatments were well tolerated. The American journal of cardiology • 2003-12-01 • Randomized Controlled Trial | N = 187 | 88/100 | PMID 14636905 ↗ |
| Can This Approach Help? Inside the Latest Research on Atorvastatin: an effective lipid-modifying agent in familial high One subject withdrew for personal reasons. Arteriosclerosis, thrombosis, and vascular biology • 1997-08-15 • Randomized Controlled Trial | N = 22 | 88/100 | PMID 9301631 ↗ |
| Can This Approach Help? Inside the Latest Research on A dose-titration and comparative study of rosuvastatin and atorvastatin in All treatments were well tolerated. Atherosclerosis • 2008-03-15 • Randomized Controlled Trial | N = 21 | 88/100 | PMID 17727860 ↗ |
Familial-genetic dilated cardiomyopathy Patient Community & “People Like Me” Threads
Filter Familial-genetic dilated cardiomyopathy community threads and patient logs by age, biological sex, dosage, and treatment duration.